Bayer Sues Johnson & Johnson Over Allegedly False Prostate Cancer Drug Marketing Claims
核心洞察
Bayer filed a federal lawsuit against Johnson & Johnson, alleging false advertising of the prostate cancer drug Erleada that claims a 51% reduction in death risk compared to Bayer's Nubeqa.
The German pharmaceutical company argues that Johnson & Johnson's comparison study contained selection bias and used non-comparable patient groups, with most Nubeqa patients receiving off-label treatment.
Bayer claims the FDA does not sanction the retrospective real-world analysis used by Johnson & Johnson as a substitute for traditional clinical trials.
Bayer filed a federal lawsuit against Johnson & Johnson on Monday, alleging that the rival pharmaceutical company is conducting a false advertising campaign for its prostate cancer drug Erleada that undermines confidence in Bayer's competing treatment Nubeqa. The complaint, filed in Manhattan federal court, seeks to halt what Bayer characterizes as scientifically flawed marketing claims that could mislead patients and healthcare providers.
Disputed Marketing Claims
According to the lawsuit, Johnson & Johnson launched an advertising campaign this month claiming that patients treated with Erleada experienced a "51% reduction in risk of death" compared to Nubeqa patients. The company allegedly presented this data as coming from testing that replicated a clinical trial and adhered to "rigorous" U.S. Food and Drug Administration standards.
Bayer disputes these claims, arguing that the comparison is fundamentally flawed. The German pharmaceutical company contends that the two patient groups were not comparable because most Nubeqa patients in the analysis received their drug off-label, creating "selection bias" that renders claims of superiority unreliable. Additionally, Bayer noted that Johnson & Johnson's study included five times more patients than the Nubeqa group.
Regulatory and Scientific Concerns
The lawsuit raises significant concerns about the scientific methodology underlying Johnson & Johnson's marketing claims. Bayer argues that the FDA does not sanction the retrospective, real-world analysis that Johnson & Johnson allegedly used as a substitute for traditional clinical trials.
"By invoking FDA authority to lend unwarranted credibility to scientifically flawed analyses, J&J has misled patients and healthcare providers," the complaint stated.
AI Amplification of Claims
Bayer's complaint also addresses the role of artificial intelligence in spreading what it considers false information. The company claims that AI systems, reflected in Google search results regarding Erleada, Nubeqa and risk of death, are amplifying Johnson & Johnson's allegedly false claims and feeding people "unsubstantiated messages about the risk of dying with Nubeqa."
Market Impact and Financial Stakes
The financial stakes in this dispute are substantial, reflecting the significant market for prostate cancer treatments. Nubeqa generated sales of approximately 1.63 billion euros ($1.92 billion) in the first nine months of 2025, while Erleada achieved sales of $2.62 billion over approximately the same period. Johnson & Johnson's drug recorded full-year sales of $3.57 billion for Erleada.
The prostate cancer market represents a critical therapeutic area, with the National Cancer Institute reporting that about 313,780 men were diagnosed with prostate cancer in the United States in 2025, and 35,770 died from the disease that year.
Legal Remedies Sought
Bayer is seeking comprehensive legal remedies, including punitive and triple damages, the recoupment of what it characterizes as ill-gotten profits, and an injunction against further false advertising. The company argues that Johnson & Johnson's marketing campaign is causing irreparable harm by threatening to erode trust in Nubeqa.
Johnson & Johnson, based in New Brunswick, New Jersey, did not immediately respond to requests for comment regarding the lawsuit.